Skip to main content

Table 2 Pharmacokinetics of iMN013 released from iMN041 formulated in FS-14 or FS-19. Where: Cmax is the maximum concentration, Tmax is the time associated with Cmax, T1/2 is the half-life, MRT is the mean residence time and AUC is the area under the curve

From: iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer

Formulation

Cmax (ng/mL)

Tmax (h)

T1/2 (h)

MRT0-last (h)

AUC0-last (h)

FS-14

1630

0.5

1.02

1.83

3624

FS-19

1770

0.5

1.40

2.27

4815